Cargando…

SARS-CoV-2: Immunopeptidomics and Other Immunological Studies

Detalles Bibliográficos
Autores principales:	Chavda, Vivek P., Redwan, Elrashdy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694091/ https://www.ncbi.nlm.nih.gov/pubmed/36423070 http://dx.doi.org/10.3390/vaccines10111975

Ejemplares similares

Immunological Studies to Understand Hybrid/Recombinant Variants of SARS-CoV-2
por: Chavda, Vivek P., et al.
Publicado: (2022)

Protein Intrinsic Disorder and Evolvability of MERS-CoV
por: Uversky, Vladimir N., et al.
Publicado: (2021)

Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2
por: Elrashdy, Fatma, et al.
Publicado: (2020)

SARS-CoV-2: A Master of Immune Evasion
por: Rubio-Casillas, Alberto, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
por: Chavda, Vivek P, et al.
Publicado: (2022)

The Emergence of Hybrid Variants of SARS-CoV-2: Towards Hybrid Immunity
por: Chavda, Vivek P., et al.
Publicado: (2023)

A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals
por: Chavda, Vivek P, et al.
Publicado: (2021)

Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity?
por: Mattar, Ehab H., et al.
Publicado: (2021)

HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review
por: Abd El-Baky, Nawal, et al.
Publicado: (2023)

Does SARS-CoV-2 Induce IgG4 Synthesis to Evade the Immune System?
por: Rubio-Casillas, Alberto, et al.
Publicado: (2023)

The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein
por: Knierman, Michael D., et al.
Publicado: (2020)

SARS-CoV-2 and other pathogenic microorganisms in the environment
por: Núñez-Delgado, Avelino, et al.
Publicado: (2021)

IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein
por: Uversky, Vladimir N., et al.
Publicado: (2023)

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
por: Chavda, Vivek P., et al.
Publicado: (2022)

Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?
por: Elrashdy, Fatma, et al.
Publicado: (2020)

Would New SARS-CoV-2 Variants Change the War against COVID-19?
por: Redwan, Elrashdy M., et al.
Publicado: (2022)

A bacterium-derived, cancer-associated immunopeptidome
por: Perreault, Claude, et al.
Publicado: (2021)

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses
por: Focosi, Daniele, et al.
Publicado: (2023)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

The immunology of SARS-CoV-2 infections and vaccines
por: Grigoryan, Lilit, et al.
Publicado: (2020)

Immunology of SARS-CoV-2 infections and vaccines
por: Schenten, Dominik, et al.
Publicado: (2021)

Antibodies, epicenter of SARS-CoV-2 immunology
por: Pecetta, Simone, et al.
Publicado: (2021)

Immunology of SARS-CoV-2 infection and vaccination
por: Lin, Baoxu, et al.
Publicado: (2023)

Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
por: Chavda, Vivek P., et al.
Publicado: (2023)

SARS-CoV-2: To be or not to be vaccinated?
por: Beauchet, Olivier
Publicado: (2021)

SARS-CoV-2 docet
por: Sarli, Leopoldo
Publicado: (2021)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Co-infection associated with SARS-CoV-2 and their management
por: Chavda, Vivek P, et al.
Publicado: (2023)

State of the Globe: “Hansen's Disease – Down but Not Out in the SARS-CoV-2 Era”
por: Thakur, Suman, et al.
Publicado: (2020)

Is the Patient Infected with SARS-CoV-2?
por: Klausner, Jeffrey D., et al.
Publicado: (2021)

Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
por: Nguyen, Tuan M., et al.
Publicado: (2020)

Immunological considerations for SARS-CoV-2 human challenge studies
por: Douglas, Alexander D., et al.
Publicado: (2020)

Epidemiological and immunological features of obesity and SARS-CoV-2
por: Nilles, Eric J, et al.
Publicado: (2020)

Epidemiological and Immunological Features of Obesity and SARS-CoV-2
por: Nilles, Eric J., et al.
Publicado: (2021)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
por: Chavda, Vivek P., et al.
Publicado: (2022)

Fundamentals of SARS-CoV-2 Biosensors
por: Torres-Torres, Carlos, et al.
Publicado: (2022)

Terrific cells for SARS-CoV-2
por: Gottschalk, Stephen
Publicado: (2022)

Deciphering SARS-CoV-2 Virologic and Immunologic Features
por: Lebeau, Grégorie, et al.
Publicado: (2020)

The Importance of Research on the Origin of SARS-CoV-2
por: Lundstrom, Kenneth, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p434pvabpcv81pmd6k25uiad4g